MAINZ BIOMED N.V.MYNZEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Mainz Biomed N.V. is a molecular diagnostics company specializing in the development and commercialization of non-invasive early detection tests for gastrointestinal cancers, primarily colorectal cancer. Its flagship product ColoAlert is approved and available across European markets, with active expansion initiatives targeting North America and other global regions.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Kreditanstalt für Wiederaufbau | — | 21.2M | — | 2024-10-07 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-13 | Caragol William J | Chief Financial Officer | Grant | 290.0K | $0.00 | $0 |
| 2026-02-13 | BAECHLER GUIDO | Chief Executive Officer | Grant | 440.0K | $0.00 | $0 |
| 2026-02-13 | Tibbitts Gregory J | Director | Grant | 45.0K | $0.00 | $0 |
| 2026-02-13 | Heinrich Dreismann | Director | Grant | 45.0K | $0.00 | $0 |
1–4 of 4